Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Low risk of prolonged SARS-CoV-2 shedding and molecular evolution in kidney transplant recipients during the Omicron era: A prospective observational study

I. Zahradka, V. Petr, J. Paces, J. Zdychova, A. Srbova, R. Limberkova, T. Suri, F. Tichanek, D. Husakova, H. Jirincova, M. Hradilova, I. Striz, O. Viklicky

. 2025 ; 25 (5) : 1002-1012. [pub] 20241203

Language English Country United States

Document type Journal Article, Observational Study

Persistent link   https://www.medvik.cz/link/bmc25015991

The aim of this prospective study was to assess the duration of culture-viable SARS-CoV-2 and to monitor the emergence of mutations in a cohort of 23 kidney transplant recipients (KTRs) from June 2022 to June 2023. Combined nares/oropharyngeal swabs were collected weekly starting as soon as possible after symptom onset. The time from symptom onset to a negative culture was 11 days (interquartile range, 8-14), while the time to negative reverse transcriptase quantitative polymerase chain reaction was 18 days (interquartile range, 15-30). Beyond the first swab, 21.7% had a positive culture, and 8.7% replicated viable virus for longer than 30 days. T cell depletion (rate ratio, 2.5; 95% confidence interval [95% CI], 1.9-3.3; P < .001) and time from transplantation (rate ratio, 0.93; 95% CI, 0.90-0.97; P = .006) were associated with the time of viable virus shedding. A cycle threshold value of 24.2 demonstrated a 91.3% negative predictive value of viability (95% credible interval [95% CrI], 76-100). The odds of viability decreased by 69% per week of infection (odds ratio, 0.31; 95% CrI, 0.12-0.76). Overall, ribonucleic acid sequencing did not show accelerated molecular evolution though mutation rate could be increased in molnupiravir-treated KTRs. In conclusion, viable SARS-CoV-2 is eliminated rapidly, the risk of virus evolution is low, and prolonged self-isolation is generally unnecessary for most KTRs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015991
003      
CZ-PrNML
005      
20250819100631.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ajt.2024.11.031 $2 doi
035    __
$a (PubMed)39638044
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zahradka, Ivan $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
245    10
$a Low risk of prolonged SARS-CoV-2 shedding and molecular evolution in kidney transplant recipients during the Omicron era: A prospective observational study / $c I. Zahradka, V. Petr, J. Paces, J. Zdychova, A. Srbova, R. Limberkova, T. Suri, F. Tichanek, D. Husakova, H. Jirincova, M. Hradilova, I. Striz, O. Viklicky
520    9_
$a The aim of this prospective study was to assess the duration of culture-viable SARS-CoV-2 and to monitor the emergence of mutations in a cohort of 23 kidney transplant recipients (KTRs) from June 2022 to June 2023. Combined nares/oropharyngeal swabs were collected weekly starting as soon as possible after symptom onset. The time from symptom onset to a negative culture was 11 days (interquartile range, 8-14), while the time to negative reverse transcriptase quantitative polymerase chain reaction was 18 days (interquartile range, 15-30). Beyond the first swab, 21.7% had a positive culture, and 8.7% replicated viable virus for longer than 30 days. T cell depletion (rate ratio, 2.5; 95% confidence interval [95% CI], 1.9-3.3; P < .001) and time from transplantation (rate ratio, 0.93; 95% CI, 0.90-0.97; P = .006) were associated with the time of viable virus shedding. A cycle threshold value of 24.2 demonstrated a 91.3% negative predictive value of viability (95% credible interval [95% CrI], 76-100). The odds of viability decreased by 69% per week of infection (odds ratio, 0.31; 95% CrI, 0.12-0.76). Overall, ribonucleic acid sequencing did not show accelerated molecular evolution though mutation rate could be increased in molnupiravir-treated KTRs. In conclusion, viable SARS-CoV-2 is eliminated rapidly, the risk of virus evolution is low, and prolonged self-isolation is generally unnecessary for most KTRs.
650    _2
$a lidé $7 D006801
650    12
$a transplantace ledvin $7 D016030
650    _2
$a prospektivní studie $7 D011446
650    _2
$a mužské pohlaví $7 D008297
650    12
$a SARS-CoV-2 $x genetika $x izolace a purifikace $x fyziologie $7 D000086402
650    12
$a COVID-19 $x virologie $x epidemiologie $7 D000086382
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a vylučování virů $7 D017201
650    _2
$a dospělí $7 D000328
650    12
$a příjemce transplantátu $7 D066027
650    12
$a molekulární evoluce $7 D019143
650    _2
$a mutace $7 D009154
650    _2
$a senioři $7 D000368
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Petr, Vojtech $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Paces, Jan $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Department of Informatics and Chemistry, University of Chemistry and Technology, Prague, Czech Republic
700    1_
$a Zdychova, Jana $u Department of Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Srbova, Alena $u Department of Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Limberkova, Radomira $u National Reference Laboratory for Influenza and Other Respiratory Viruses, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Suri, Timotej $u National Reference Laboratory for Influenza and Other Respiratory Viruses, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Tichánek, Filip $u Department of Data Science, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 xx0334827
700    1_
$a Husakova, Denisa $u National Reference Laboratory for Influenza and Other Respiratory Viruses, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Jirincova, Helena $u National Reference Laboratory for Influenza and Other Respiratory Viruses, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Hradilova, Miluse $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Striz, Ilja $u Department of Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Viklicky, Ondrej $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Transplantation Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Electronic address: ondrej.viklicky@ikem.cz
773    0_
$w MED00006447 $t American journal of transplantation $x 1600-6143 $g Roč. 25, č. 5 (2025), s. 1002-1012
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39638044 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250819100614 $b ABA008
999    __
$a ok $b bmc $g 2366682 $s 1253116
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 25 $c 5 $d 1002-1012 $e 20241203 $i 1600-6143 $m American journal of transplantation $n Am J Transplant $x MED00006447
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options